LKB1 mutations
advanced non-small-cell lung cancer (NSCLC)
chemotherapy
docetaxel
platinum chemotherapy
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
15
03
2020
revised:
14
04
2020
accepted:
15
04
2020
entrez:
30
5
2020
pubmed:
30
5
2020
medline:
20
7
2021
Statut:
ppublish
Résumé
In patients with advanced lung adenocarcinoma, the impact of The multicenter TAILOR trial randomised patients with Out of 222 patients randomised in the TAILOR trial, left-over tumour tissues were available for 188 patients, and 120 patients with evaluable Among advanced NSCLC patients receiving two lines of systemic therapy,
Identifiants
pubmed: 32467099
pii: S2059-7029(20)30037-5
doi: 10.1136/esmoopen-2020-000748
pmc: PMC7259832
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Taxoids
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
STK11 protein, human
EC 2.7.11.1
AMP-Activated Protein Kinase Kinases
EC 2.7.11.3
Types de publication
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e000748Informations de copyright
© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.
Déclaration de conflit d'intérêts
Competing interests: Dr. Garassino reported personal fees from Merck, BMS, AstraZeneca, Roche, Takeda, Celgene, Pfizer, and GSK. No other disclosures were reported.
Références
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Oncotarget. 2015 Oct 20;6(32):34014-22
pubmed: 26416458
Oncotarget. 2016 Nov 8;7(45):73389-73401
pubmed: 27705915
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Clin Lung Cancer. 2019 May;20(3):e413-e417
pubmed: 30617039
Cell. 2003 Nov 26;115(5):577-90
pubmed: 14651849
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Clin Cancer Res. 2017 Jul 1;23(13):3316-3324
pubmed: 28119362
Biochem Pharmacol. 2018 Oct;156:479-490
pubmed: 30222967
J Thorac Oncol. 2018 Nov;13(11):1692-1704
pubmed: 30149143
Lancet Oncol. 2013 Sep;14(10):981-8
pubmed: 23883922
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
J Biol Chem. 2005 Apr 15;280(15):15158-64
pubmed: 15713674
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Cancer Cell. 2013 Feb 11;23(2):143-58
pubmed: 23352126
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Nature. 2008 Oct 23;455(7216):1069-75
pubmed: 18948947
Nature. 2012 May 09;485(7400):661-5
pubmed: 22660331
Science. 2011 Jan 28;331(6016):456-61
pubmed: 21205641
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):251-62
pubmed: 22436748
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Cancer Res. 2002 Jul 1;62(13):3659-62
pubmed: 12097271
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Lancet Oncol. 2012 Mar;13(3):247-55
pubmed: 22341744
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3329-35
pubmed: 14985505
Clin Cancer Res. 2015 Jun 15;21(12):2851-60
pubmed: 25737507
Cancer Discov. 2019 Jan;9(1):34-45
pubmed: 30297358